Product Description
Mechanisms of Action: Protein Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Chile | China | Croatia | Cyprus | Egypt | Finland | France | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Lebanon | Malaysia | Malta | Netherlands | New Zealand | Norway | Pakistan | Poland | Russia | Serbia | South Africa | Spain | Sweden | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United States | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Baxter Healthcare
Company Location: Eastern America
Company CEO: José E. Almeida
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Hyperphagia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06065202 |
SeND Home | P2 |
Recruiting |
Hyperphagia |
2026-03-30 |
2025-11-25 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/28/2026 |
News Article |
Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G pTau 217 CSF Assay for Research Use Only |
|
01/20/2026 |
News Article |
Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers a New Era in High-Throughput Kinase Inhibitor Screening |
|
12/22/2025 |
News Article |
Quanterix Announces Landmark Nature Study Redefining Alzheimer's Disease Neuropathology Prevalence |
|
11/13/2025 |
News Article |
IFEEDER's Latest Report Sheds Light on China's Control of Critical Feed Inputs |